This is the second time the company has cut down prices of Zepbound on LillyDirect. Eli Lilly said it was making the weight ...

Eli Lilly and Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...

New WHO guidance calls for a worldwide obesity treatment “ecosystem” to ensure that GLP-1 weight-loss drugs are used fairly ...

Lilly's Zepbound price cuts ranged from $50 to $100, depending on the dosage, for consumers who pay cash via the drugmaker's ...

A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a ...

In the early November announcement of its agreement with the government, Lilly pledged to reduce the self-pay price of ...

The share price of Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) hit a four-year low Monday, falling below $44 a share in early trading, a level the stock hasn't seen since July 2021. What's ...

Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment ...

Investors will want to see these key developments concerning Novo Nordisk's pipeline of new treatments. The company revealed ...

Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong ...

In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.